Dorien M A Berends-van der Meer

Author PubWeight™ 13.91^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.	N Engl J Med	2009	5.79
2	Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.	Clin Cancer Res	2008	2.06
3	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.	Proc Natl Acad Sci U S A	2010	1.67
4	Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.	Clin Cancer Res	2008	1.66
5	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.	J Transl Med	2013	1.02
6	A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.	Cancer Immunol Immunother	2012	0.97
7	The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.	Cancer Immunol Immunother	2013	0.89